GBV 006

Drug Profile

GBV 006

Alternative Names: GBV-006

Latest Information Update: 26 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University School of Medicine
  • Developer Globavir Biosciences
  • Class Antivirals
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ebola virus infections
  • Phase I Dengue
  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 18 Dec 2017 Globavir Biosciences collaborates with the SingHealth Duke-NUS Academic Medical Centre for Dengue
  • 01 Sep 2016 Phase-I clinical trials in Dengue in USA (unspecified route) before September 2016
  • 01 Sep 2016 Phase-II clinical trials in Ebola virus infections in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top